Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanomaMore about Open Access at the Crick
Authors listE Ghorani Rachel Rosenthal N McGranahan JL Reading M Lynch KS Peggs Charles Swanton SA Quezada
Cancer mutations generate novel (neo-)peptides recognised by T cells, but the determinants of recognition are not well characterised. The difference in predicted class I major histocompatibility complex (MHC-I) binding affinity between wild-type and corresponding mutant peptides (differential agretopicity index; DAI) may reflect clinically relevant cancer peptide immunogenicity. Our aim was to explore the relationship between DAI, measures of immune infiltration and patient outcomes in advanced cancer.
Journal Annals of Oncology
Issue number 1